Edition:
United Kingdom

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

0.95USD
19 Jan 2018
Change (% chg)

$0.15 (+18.65%)
Prev Close
$0.80
Open
$0.90
Day's High
$1.04
Day's Low
$0.88
Volume
1,414,601
Avg. Vol
43,301
52-wk High
$3.11
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

‍Armistice Capital​ Reports 5.2 Pct Passive Stake In Intellipharmaceutics International
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Intellipharmaceutics International Inc ::‍ARMISTICE CAPITAL LLC​ REPORTS A 5.2 PERCENT PASSIVE STAKE IN INTELLIPHARMACEUTICS INTERNATIONAL INC AS OF NOV 22 - SEC FILING.  Full Article

Intellipharmaceutics launches additional strengths of generic Focalin XR in U.S.​
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Intellipharmaceutics International Inc ::SAYS ‍LAUNCHED 5&40 MG STRENGTHS OF ITS GENERIC FOCALIN XR CAPSULES IN U.S​.SAYS UNDER DEAL BETWEEN CO & PAR, CO RECEIVES QTRLY PROFIT-SHARE PAYMENTS ON PAR'S U.S. SALES OF GENERIC FOCALIN XR.  Full Article

Intellipharmaceutics announces US$4 mln registered direct offering
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Intellipharmaceutics International Inc ::Intellipharmaceutics announces US$4 million registered direct offering.Intellipharmaceutics - ‍entered securities purchase agreements with investors providing for purchase ,sale of 3.6 million shares at US$1.10 per share​.  Full Article

Intellipharmaceutics- Q3 loss per share $0.08
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics announces third quarter 2017 results.Q3 loss per share $0.08.Q3 revenue $1.2 million versus $600,000.Intellipharmaceutics International Inc - ‍ expects revenue from generic Seroquel XR to increase going forward​.  Full Article

FDA Staff raises concerns about Intellipharma's opioid painkiller
Monday, 24 Jul 2017 

July 24 (Reuters) - Intellipharmaceutics International Inc -:FDA Staff: no new safety signals were identified with Intellipharma's opioid painkiller Rexista beyond what is already known for oxycodone products.FDA Staff: Intellipharma's opioid painkiller Rexista tablets are relatively easier to reduce into fine particles than OxyContin tablets.FDA Staff: most solvents had similar or lower extraction recoveries from Rexista tablets than from OxyContin tablets.FDA Staff: at the correct combination of testing conditions, Rexista tablet samples were similar or less syringeable than OxyContin .FDA Staff: not easy to separate/eliminate blue dye & nasal irritant in Rexista, without using extensive chemistry knowledge.FDA Staff: using complex extraction procedures, oxycodone base can be achieved with similar or lower purity & yield from Rexista than from OxyContin .FDA Staff: varying extent of physical manipulations progressively increase the oxycodone dissolution rate from both Rexista and OxyContin .FDA Staff: even with the largest extent of manipulation, Rexista still retained some extended-release characteristics.FDA Staff: Rexista tablets are less efficient to vaporize than OxyContin tablets.FDA Staff: There were no human abuse liability studies submitted with the marketing application for Rexista.FDA Staff: Safety info collected in Rexista pharmacokinetic studies was of limited value since these were generally single-dose studies.  Full Article

Intellipharma says Par Pharma launches additional strengths of generic Focalin
Wednesday, 24 May 2017 

May 24 (Reuters) - Intellipharmaceutics International Inc :Intellipharmaceutics reports on launch of additional strengths of generic focalin xr® by par pharmaceutical.Intellipharmaceutics - par pharmaceutical has launched 10 and 20 mg strengths of its generic focalin xr capsules in u.s.Intellipharmaceutics international inc says expects remaining 5 and 40 mg strengths to be launched in near future.Intellipharmaceutics -under a licensing and commercialization , co receives quarterly profit-share payments on par's u.s. Sales of generic focalin xr.  Full Article

Intellipharmaceutics signs an exclusive license deal with Mallinckrodt
Tuesday, 11 Oct 2016 

Intellipharmaceutics International Inc : Intellipharmaceutics signs an exclusive license and commercial supply agreement with mallinckrodt . Intellipharmaceutics international inc - Intellipharmaceutics will receive a non-refundable upfront payment of US$3 million in October 2016 . Intellipharmaceutics International Inc - has agreed to manufacture and supply licensed products exclusively for mallinckrodt . Intellipharmaceutics international inc - Mallinckrodt has agreed that Intellipharmaceutics will be its sole supplier of licensed products marketed in u.s .Intellipharmaceutics International- agreement provides for company to have long-term profit sharing arrangement with respect to licensed products.  Full Article

Intellipharmaceutics announces FDA tentative approval for generic Seroquel XR
Friday, 7 Oct 2016 

Intellipharmaceutics International Inc : Says received tentative approval from u.s. Fda for co's new drug application for quetiapine fumarate . Launch of its generic versions of seroquel xr is subject to fda final approval of co's anda . Intellipharmaceutics announces fda tentative approval for generic seroquel xr® . Intellipharmaceutics announces fda tentative approval for generic seroquel xr® .Pursuant to settlement between co & astrazeneca in 2012, co is permitted to launch generic versions of seroquel xr on nov 1 2016.  Full Article

Intellipharmaceutics reports Q2 loss per share $0.08
Wednesday, 13 Jul 2016 

Intellipharmaceutics International Inc : Intellipharmaceutics announces second quarter 2016 results .Q2 loss per share $0.08.  Full Article

Intellipharmaceutics says Rexista results indicate no food effect
Tuesday, 5 Jul 2016 

Intellipharmaceutics International Inc : Intellipharmaceutics reports update on Rexista XR: FDA grants waiver of NDA filing fee, and topline pharmacokinetics results indicate no food effect . FDA has completed its review of our request and has granted a waiver of $1,187,100 application fee for Rexista XR . Food effect study showed that Rexista XR can be administered with or without a meal .Company plans to file NDA for Rexista XR in August of 2016.  Full Article

BRIEF-‍Armistice Capital​ Reports 5.2 Pct Passive Stake In Intellipharmaceutics International

* ‍ARMISTICE CAPITAL LLC​ REPORTS A 5.2 PERCENT PASSIVE STAKE IN INTELLIPHARMACEUTICS INTERNATIONAL INC AS OF NOV 22 - SEC FILING Source text: (http://bit.ly/2A42XdW) Further company coverage: